Table 1. Characteristics of 986 lung cancer patients recruited from central and eastern Europe and included in analysis of circulating proteins.
| Characteristics | Never smoking (N=244) | Ever smoking (N=742) | Total (N=986) |
|---|---|---|---|
| Age at diagnosis (years), mean (SD) | 65.1 (10.4) | 64.1 (8.27) | 64.4 (8.84) |
| Sex, n (%) | |||
| Female | 197 (80.7) | 132 (17.8) | 329 (33.4) |
| Male | 47 (19.3) | 610 (82.2) | 657 (66.6) |
| Centers†, n (%) | |||
| Czechia | 3 (1.2) | 21 (2.8) | 24 (2.4) |
| Poland | 24 (9.8) | 223 (30.1) | 247 (25.1) |
| Romania | 4 (1.6) | 30 (4.0) | 34 (3.4) |
| Russian Federation | 213 (87.3) | 379 (51.1) | 592 (60.0) |
| Serbia | 0 (0.0) | 89 (12.0) | 89 (9.0) |
| Year at diagnosis, n (%) | |||
| 2007–2010 | 70 (28.7) | 152 (20.5) | 222 (22.5) |
| 2011–2013 | 94 (38.5) | 421 (56.7) | 515 (52.2) |
| 2014–2016 | 80 (32.8) | 169 (22.8) | 249 (25.3) |
| Education, n (%) | |||
| Elementary | 47 (19.3) | 273 (36.8) | 320 (32.5) |
| High school | 88 (36.1) | 288 (38.8) | 376 (38.2) |
| University | 109 (44.7) | 179 (24.1) | 288 (29.3) |
| Missing | 0 | 2 | 2 |
| Regular alcohol intake, n (%) | |||
| Never | 203 (83.2) | 354 (47.7) | 557 (56.5) |
| Ever | 41 (16.8) | 388 (52.3) | 429 (43.5) |
| BMI at diagnosis | |||
| Mean (SD) | 28.0 (4.74) | 26.0 (4.33) | 26.5 (4.52) |
| Missing | 0 | 1 | 1 |
| Smoking pack-years | |||
| Mean (SD) | NA | 43.2 (21.6) | 43.2 (21.6) |
| Missing | NA | 3 | 3 |
| Histology, n (%) | |||
| Adenocarcinoma | 211 (86.5) | 297 (40.0) | 508 (51.5) |
| Squamous cell carcinoma | 33 (13.5) | 445 (60.0) | 478 (48.5) |
| Stage, n (%) | |||
| IA | 90 (36.9) | 170 (22.9) | 260 (26.4) |
| IB | 66 (27.0) | 202 (27.2) | 268 (27.2) |
| IIA | 25 (10.2) | 122 (16.4) | 147 (14.9) |
| IIB | 16 (6.6) | 77 (10.4) | 93 (9.4) |
| IIIA | 47 (19.3) | 171 (23.0) | 218 (22.1) |
| Chemotherapy, n (%) | 49 (20.1) | 205 (27.6) | 254 (25.8) |
| Radiation therapy, n (%) | 36 (14.8) | 135 (18.2) | 171 (17.3) |
| All cause death, n (%) | 86 (35.2) | 367 (49.5) | 453 (45.9) |
| Lung cancer death, n (%) | 64 (26.2) | 216 (29.1) | 280 (28.4) |
| Survival probability (%), OS (95% CI) | |||
| 1-year | 90.6 (87.0–94.3) | 82.6 (79.9–85.4) | 84.1 (81.6–86.6) |
| 3-year | 77.7 (72.7–83.2) | 59.6 (56.2–63.3) | 62.7 (59.5–66.0) |
| 5-year | 63.1 (57.1–69.7) | 46.6 (42.9–50.7) | 48.9 (45.5–52.6) |
†, patients were recruited from 2 sites in Russian Federation (departments of thoracic surgery in N.N. Blokhin National Medical Research Center of Oncology, and the City Clinical Oncological Hospital No. 1 in Moscow), 3 sites in Czech Republic (Motol University Hospital in Prague, Masaryk Memorial Cancer Institute in Brno and University Hospital Olomouc in Olomouc), 1 site in Romania (Marius Nasta Institute of Pneumology in Bucharest), 1 site in Serbia (Clinical Centre of Serbia in Belgrade), and 2 sites in Poland (Institute of Tuberculosis and Lung Diseases in Warsaw, and Military Medical Academy in Lodz). SD, standard deviation; OS, overall survival; CI, confidence interval; NA, no observation.